Thank you for your interest in the Indivior Independent Medical Education Grants Program.
Independent Medical Education – Indivior provides support to accredited educational programs and activities in the United States that provide for increased understanding of scientific, clinical and healthcare issues related to Indivior's education areas of interest. Requests for support for non-accredited programs and activities will not be considered.
Indivior will consider requests for funding with regard to the following education areas of interest:
Opioid Use Disorder (OUD)
Opioid Overdose Treatment
Schizophrenia
Before submitting a request, please review the information provided on the Overview, Grants Process, and Request a Grant pages. Questions should be directed by email to educationalgrants@indivior.com.
This information pertains only to organizations based in the United States.
Education Areas of Interest
Standard of care for the treatment of OUD as reflected in current and evidence-based updates to guidelines
Awareness of current guidelines for the treatment of OUD
Optimal therapeutic management and treatment of patients with OUD including education
Rationale for use of a partial opioid agonist for the treatment of OUD
Awareness of substance use disorders including OUD
Optimizing treatment/treatment strategies across the treatment continuum (i.e., initiation, maintenance, cessation/long term management)
Improving treatment adherence, relapse, overdose, and abuse/misuse/diversion
Recognizing the barriers to the treatment of OUD
Evaluation in sub-populations, patients at risk, and underserved patients
Long term treatment outcomes in patients with OUD (including real-world evidence, quality of life and health economic assessments)
Access challenges: patients in the criminal justice system, geographic (e.g., rural areas where travel is a challenge to health care), homelessness (e.g., mobile health)
Access challenges within health systems/integrated delivery networks (IDNs)
Clinical or healthcare issues related to OUD
Social determinants of health (SDoH) and utilization of extended-release medications for OUD
Continuity of care during the COVID-19 pandemic (e.g., telemedicine)
Overcoming barriers to treatment and sharing successful strategies to treat opioid overdoses
Strategies for transitioning to a medication for opioid use disorder treatment following an opioid overdose
Signs, symptoms, and treatment of opioid overdose; understanding the evolution of the opioid crisis and the role of synthetic opioids
Emerging pharmacological approaches for the treatment of opioid overdose
Strategies to reduce the risk of overdose and manage individuals post-overdose
Strategies to encourage and optimize the participation of first responders (e.g., emergency medical services, law enforcement) in the treatment of opioid overdose
Standard of care for the treatment of schizophrenia as reflected in current and evidence-based updates to guidelines
Awareness of current guidelines for the treatment of schizophrenia
Optimal therapeutic management and treatment of patients with schizophrenia
Recognition and improvement of treatment adherence in patients with schizophrenia with a focus on how long-acting injectables can improve adherence
Timing of long-acting injectable intervention (e.g., with regards to patient journey; acute-care settings) and health-outcome assessments, including long-term and short-term outcomes; reducing relapse and/or re-hospitalization in patients with schizophrenia
Recognizing the barriers to providing treatment for patients with schizophrenia
Evaluation in sub-populations, patients at risk, and underserved patients, including within the criminal justice system, the United States Veterans Health Administration, or the United States Indian Health Service
Long-term treatment outcomes in patients with schizophrenia (including real-world evidence, quality-of-life, and health-economic assessments)
Scientific, clinical, or healthcare issues related to schizophrenia
